Effect of newer oral antiviral agents on future therapy of chronic hepatitis B

2010 ◽  
Vol 15 (5) ◽  
pp. 801
Author(s):  
Robert P Perrillo ◽  
Patrick Marcellin
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Antiviral Agents ◽  
Future Therapy

Effect of newer oral antiviral agents on future therapy of chronic hepatitis B

2010 ◽  
Vol 15 (1) ◽  
pp. 13-22 ◽  
Author(s):  
Robert P Perrillo ◽  
Patrick Marcellin
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Antiviral Agents ◽  
Future Therapy

Association of intrahepatic cccDNA reduction with the improvement of liver histology in chronic hepatitis B patients receiving oral antiviral agents

2011 ◽  
Vol 83 (4) ◽  
pp. 602-607 ◽  
Author(s):  
Pin-Nan Cheng ◽  
Wen-Chun Liu ◽  
Hung-Wen Tsai ◽  
I-Chin Wu ◽  
Ting-Tsung Chang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Antiviral Agents ◽  
Liver Histology

scholarly journals The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy

Viruses ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 934 ◽  
Author(s):  
Samuel Hall ◽  
Jessica Howell ◽  
Kumar Visvanathan ◽  
Alexander Thompson
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Antiviral Agents ◽  
Standard Of Care ◽  
Current Standard ◽  
Hbsag Loss ◽  
Personalised Treatment ◽  
Treat All

Over 257 million individuals worldwide are chronically infected with the Hepatitis B Virus (HBV). Nucleos(t)ide analogues (NAs) are the first-line treatment option for most patients. Entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are both potent, safe antiviral agents, have a high barrier to resistance, and are now off patent. They effectively suppress HBV replication to reduce the risk of cirrhosis, liver failure, and hepatocellular carcinoma (HCC). Treatment is continued long-term in most patients, as NA therapy rarely induces HBsAg loss or functional cure. Two diverging paradigms in the treatment of chronic hepatitis B have recently emerged. First, the public health focussed “treat-all” strategy, advocating for early and lifelong antiviral therapy to minimise the risk of HCC as well as the risk of HBV transmission. In LMICs, this strategy may be cost saving compared to monitoring off treatment. Second, the concept of “stopping” NA therapy in patients with HBeAg-negative disease after long-term viral suppression, a personalised treatment strategy aiming for long-term immune control and even HBsAg loss off treatment. In this manuscript, we will briefly review the current standard of care approach to the management of hepatitis B, before discussing emerging evidence to support both the “treat-all” strategy, as well as the “stop” strategy, and how they may both have a role in the management of patients with chronic hepatitis B.

scholarly journals Effects of antiviral agents and HBV genotypes on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients

2008 ◽  
Vol 14 (8) ◽  
pp. 1268 ◽  
Author(s):  
Hai-Ying Lu ◽  
Li-Wei Zhuang ◽  
Yan-Yan Yu ◽  
Chong-Wen Si ◽  
Jun Li ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Antiviral Agents ◽  
Circular Dna ◽  
Covalently Closed Circular Dna ◽  
Hbv Genotypes ◽  
Positive Chronic Hepatitis

New Antiviral Agents for the Therapy of Chronic Hepatitis B Virus Infection

Intervirology ◽  
1999 ◽  
Vol 42 (2-3) ◽  
pp. 125-144 ◽  
Author(s):  
Fabien Zoulim ◽  
Christian Trepo
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Antiviral Agents ◽  
Hepatitis B Virus Infection ◽  
Chronic Hepatitis B Virus ◽  
B Virus
Sign in / Sign up

Export Citation Format

Share Document